

Applicant: Emile Loria et al.
U.S. Serial No: 09/867,159
Filed: May 29, 2001
Page: 2

Please amend the application as follows:

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators.

Claims 1 to 63. (Canceled)

Claim 64. (Withdrawn) A use of a first allergen or of an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said first allergen, for preparing a pharmaceutical composition that is useful for treating or preventing an allergy caused by a second allergen different from the first allergen.

Claim 65. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid.

Claim 66. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid, and said second allergen is not a cystine protease of said acarid.

Claim 67. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of a mite.

Claim 68. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is at least one peptide epitope of a cystine protease.

Claim 69. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is at least one peptide epitope of a cystine protease having the sequence SEQ ID NO: 2.

Applicant: Emile Loria et al.
U.S. Serial No: 09/867,159
Filed: May 29, 2001
Page: 3

Claim 70. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is a peptide or a mixture of peptide which are chosen from the group consisting of the peptides having the sequence SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

Claim 71. (Withdrawn) The use as claimed in claim 67, wherein said first allergen is natural and is obtained by extraction of *D. Pteronyssinus* and/or *D. Ferinae* from mites

Claim 72. (Withdrawn) The use as claimed in claim 67, wherein said second allergen is not a cystine protease of said mite.

Claim 73. (Withdrawn) A method for making a pharmaceutical composition that is useful for treating an allergy caused by a first allergen comprising the steps of :

providing a second allergen different from said first allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said second allergen; and

preparing said pharmaceutical composition from said second allergen or said isolated nucleic acid molecule.

Claim 74. (Currently Amended) An anti-allergic pharmaceutical composition comprising

(a) an acarid allergen ~~comprising~~ consisting of

- i. ~~the allergen encoded by the polynucleotide of SEQ ID NO:1,~~
- ii. ~~the allergen as shown in SEQ ID NO:2,~~
- i. ~~iii.~~ the allergen as shown in SEQ ID NO:3,
- ii. ~~iv.~~ the allergen as shown in SEQ ID NO:4, and/or
- iii. ~~v.~~ the allergen as shown in SEQ ID NO:5,

Applicant: Emile Loria et al.
U.S. Serial No: 09/867,159
Filed: May 29, 2001
Page: 4

- (b) an antihistamine selected from the group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxyzine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate and doxylamine,
- (c) an inhibitor of histamine synthesis, wherein the inhibitor comprises an inhibitor of histidine decarboxylase, and
- (d) a pharmaceutically acceptable carrier.

Claim 75. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D.Pteronyssinus*.

Claim 76. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D.Farinae*.

Claim 77. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is a cystine protease.

Claim 78. (Previously Presented) The pharmaceutical composition of claim 82, wherein the inhibitor of histidine decarboxylase is tritoqualine.

Claim 79. (Currently Amended) A method for ~~reducing~~ treating an allergic hypersensitivity reaction comprising administration of the pharmaceutical composition of claim 74 to a subject.

Claim 80. (Currently Amended) The method of claim 79, wherein ~~reducing~~ the allergic hypersensitivity reaction ~~treats allergic hypersensitivity~~ is reduced in the subject.

Applicant: Emile Loria et al.
U.S. Serial No: 09/867,159
Filed: May 29, 2001
Page: 5

Claim 81. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is present in an amount of 1 to 1500 micrograms or 10 to 150 micrograms.

Claim 82. (Previously Presented) The pharmaceutical composition of claim 74, wherein the antihistamine is present in an amount of 1 to 2000 milligrams or 5 to 200 milligrams.

Claim 83. (Currently Amended) The pharmaceutical composition of claim 74, wherein the inhibitor of histamine synthesis is present in an amount of between 1 to 2000 milligrams, 5 to 200 milligrams or 10 to 300 milligrams.